QUOTE AND NEWS
Benzinga  Nov 3  Comment 
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of October the Company enrolled 22 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its...
StreetInsider.com  Oct 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CEL-SCI+Corp+%28CVM%29+Prices+%246M+Common%2C+Warrants+Offering+at+76c+Apiece/9927029.html for the full story.
DailyFinance  Sep 10  Comment 
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the University of Minnesota’s Masonic Cancer Center has becomes the 7th clinical site in the U.S. to join its Phase III head and neck cancer clinical trial of its...
StreetInsider.com  Aug 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CEL-SCI+Corp.+%28CVM%29+Announces+Expansion+of+Multikine+Phase+III+Head+and+Neck+Cancer+Trial/9765327.html for the full story.
SeekingAlpha  Aug 12  Comment 
BySharon di Stefano: Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled "I-O" first by Bristol-Myers Squibb Co. (NYSE:BMY),...
DailyFinance  Aug 1  Comment 
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and...
StreetInsider.com  Aug 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CEL-SCI+Corp.+%28CVM%29+Surpasss+One-Quarter+Enrollment+in+Multikine+Phase+III/9712124.html for the full story.
Benzinga  Jul 22  Comment 
CEL-SCI Corporation (NYSE MKT: CVM) today announced that Turkey's Ministry of Health has cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer...
StreetInsider.com  Jul 22  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CEL-SCI+Corp.+%28CVM%29+Approves+to+Expand+Multikine+Phase+III+in+Turkey/9678333.html for the full story.




 

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.

CEL-SCI's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is an immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. Data from Phase I and Phase II clinical trials suggest that Multikine simulates the activities of a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki